Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Expanded Indication for SPIRIVA Respimat for Patients 6 Years and Older

By Boehringer Ingelheim | March 19, 2018

Boehringer Ingelheim announced that an expanded indication for SPIRIVA Respimat (tiotropium Respimat) as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the past year, has been accepted by the regulatory authorities in the EU. 

“Almost 1 in 2 people with asthma of all ages continue to experience symptoms despite their existing treatment. Asthma symptoms significantly impact daily life including education, work, school, social lives and sleep,” said Professor Eckard Hamelmann, Head of the Paediatric Department, Children’s Center Bethel in Bielefeld, Germany. “This new approval, supported by extensive data from the UniTinA-asthma clinical trial programme, recognises the benefit tiotropium Respimat® add-on therapy can bring to adolescents and children with asthma as young as 6 years old.” 

Tiotropium Respimat is part of a class of medicines called long-acting muscarinic antagonists (LAMA) and is the only one of its kind approved for asthma. It works differently from other treatment options by complementing other maintenance therapies (usually ICS/LABA‡) to improve lung function, improve symptom control and reduce the risk of exacerbations or asthma attacks. The safety profile of tiotropium Respimat across all age groups is comparable to placebo.

The expanded indication following finalisation of the decentralised European regulatory procedure on 9 March 2018 is supported by the completion of the large scale UniTinA-asthma clinical trial programme. This demonstrated that tiotropium Respimat add-on therapy is effective and well tolerated in asthma patients as young as 6 years old.

“Boehringer Ingelheim is committed to improving the lives of people with respiratory disease,” said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Respiratory, Boehringer Ingelheim. “Asthma symptoms impact all areas of patients’ lives, often leaving them feeling a sense of confinement, their daily activities defined by their disease. We believe that the expanded EU indication for tiotropium Respimat will bring benefit to more people with symptomatic asthma aged 6 years and above.”

Tiotropium is delivered via Respimat, the only inhaler that actively delivers a unique mist, meaning patients only need a minimal inhalation effort for the medication to go deep into the lungs. It can be inhaled successfully and without help by the majority of children aged 6 years and above.

Tiotropium Respimat was previously approved for use in the EU as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 µg budesonide/day or equivalent) and long-acting beta2-agonists and who experienced one or more severe exacerbations in the previous year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE